Methylene blue treatment for residual symptoms of bipolar disorder: Randomised crossover study

British Journal of Psychiatry

Volumn 210, Issue 1, 2017, Pages 54-60

  Alda, Martin ^a   McKinnon, Margaret ^b,c   Blagdon, Ryan ^a   Garnham, Julie ^d   MacLellan, Susan ^d   O'Donovan, Claire ^a   Hajek, Tomas ^a   Nair, Cynthia ^e   Dursun, Serdar ^f   MacQueen, Glenda ^g  

^a DALHOUSIE UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Mood Disorders Program   (Canada)

^d Capital District Health Authority   (Canada)

^e Prince Albert   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LAMOTRIGINE; METHYLENE BLUE; PLACEBO; AMINO ACID RECEPTOR BLOCKING AGENT; ENZYME INHIBITOR; NEUROPROTECTIVE AGENT; TRIAZINE DERIVATIVE;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL OUTCOME; COGNITIVE DEFECT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUID RETENTION; HAMILTON ANXIETY SCALE; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HUMAN; LOW DRUG DOSE; MALE; MANIA; MINIMAL RESIDUAL DISEASE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; URINARY TRACT BURNING; URINARY TRACT DISEASE; URINE COLOR; YOUNG MANIA RATING SCALE; ANXIETY; COGNITIVE DYSFUNCTION; COMBINATION DRUG THERAPY; COMPLICATION; MIDDLE AGED; OUTCOME ASSESSMENT; YOUNG ADULT;

ADULT; ANXIETY; BIPOLAR DISORDER; COGNITIVE DYSFUNCTION; CROSS-OVER STUDIES; DEPRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; METHYLENE BLUE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); TRIAZINES; YOUNG ADULT;

EID: 85009078239     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.115.173930     Document Type: Article

References (48)

1. Judd LL, Schettler PJ, Akiskal HS, Coryell W, Leon AC, Maser JD, et al. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Arch Gen Psychiatry 2008; 65: 386-94.
2. Scott J, Leboyer M, Hickie I, Berk M, Kapczinski F, Frank E, et al. Clinical staging in psychiatry: A cross-cutting model of diagnosis with heuristic and practical value. Br J Psychiatry 2013; 202: 243-5.
3. Bourne C, Aydemir O, Balanza-Martinez V, Bora E, Brissos S, Cavanagh JT, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: An individual patient data meta-analysis. Acta Psychiatr Scand 2013; 128: 149-62.
4. Kessing LV. Cognitive impairment in the euthymic phase of affective disorder. Psychol Med 1998; 28: 1027-38.
5. Rubinsztein JS, Michael A, Paykel ES, Sahakian BJ. Cognitive impairment in remission in bipolar affective disorder. Psychol Med 2000; 30: 1025-36.
6. van Gorp WG, Altshuler L, Theberge DC, Wilkins J, Dixon W. Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence. A preliminary study. Arch Gen Psychiatry 1998; 55: 41-6.
7. Tham A, Engelbrektson K, Mathe AA, Johnson L, Olsson E, Aberg-Wistedt A. Impaired neuropsychological performance in euthymic patients with recurring mood disorders. J Clin Psychiatry 1997; 58: 26-9.
8. Naylor GJ, Dick DA, Johnston BB, Hopwood SE, Dick EG, Smith AH, et al. Possible explanation for therapeutic action of lithium, and a possible substitute (methylene-blue). Lancet 1981; 2: 1175-6.
9. Narsapur SL, Naylor GJ. Methylene blue. A possible treatment for manic depressive psychosis. J Affect Disord 1983; 5: 155-61.
10. Thomas RD, Callender K. Methylene blue in treatment of bipolar illness. Biol Psychiatry 1985; 20: 120-1.
11. Naylor GJ, Smith AH, Connelly P. Methylene blue in mania. Biol Psychiatry 1988; 24: 941-2.
12. Naylor GJ, Martin B, Hopwood SE, Watson Y. A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manicdepressive psychosis. Biol Psychiatry 1986; 21: 915-20.
13. Naylor GJ, Smith AH, Trotter P. Catalysis of the reduction of vanadate by psychotropic drugs. Neuropharmacology 1983; 22: 653-6.
14. Naylor GJ, Smith AH, Connelly P. A controlled trial of methylene blue in severe depressive illness. Biol Psychiatry 1987; 22: 657-9.
15. Eroglu L, Caglayan B. Anxiolytic and antidepressant properties of methylene blue in animal models. Pharmacol Res 1997; 36: 381-5.
16. Wegener G, Volke V, Rosenberg R. Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo. Br J Pharmacol 2000; 130: 575-80.
17. Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol 2012; 96: 32-45.
18. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2013. Bipolar Disord 2013; 15: 1-44.
19. von Wegerer J, Hesslinger B, Berger M, Walden J. A calcium antagonistic effect of the new antiepileptic drug lamotrigine. Eur Neuropsychopharmacol 1997; 7: 77-81.
20. Zona C, Avoli M. Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture. Epilepsia 1997; 38: 522-5.
21. Wang SJ, Sihra TS, Gean PW. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuroreport 2001; 12: 2255-8.
22. Hassel B, Tauboll E, Gjerstad L. Chronic lamotrigine treatment increases rat hippocampal GABA shunt activity and elevates cerebral taurine levels. Epilepsy Res 2001; 43: 153-63.
23. Cunningham MO, Jones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 2000; 39: 2139-46.
24. Crumrine RC, Bergstrand K, Cooper AT, Faison WL, Cooper BR. Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest. Stroke 1997; 28: 2230-6.
25. Ingram DK, Spangler EL, Iijima S, Kuo H, Bresnahan EL, Greig NH, et al. New pharmacological strategies for cognitive enhancement using a rat model of age-related memory impairment. Ann NY Acad Sci 1994; 717: 16-32.
26. Schuman EM, Meffert MK, Schulman H, Madison DV. An ADPribosyltransferase as a potential target for nitric oxide action in hippocampal long-term potentiation. Proc Natl Acad Sci USA 1994; 91: 11958-62.
27. Park C, Kang M, Kwon YK, Chung JH, Ahn H, Huh Y. Inhibition of neuronal nitric oxide synthase enhances cell proliferation in the dentate gyrus of the adrenalectomized rat. Neurosci Lett 2001; 309: 9-12.
28. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: Rationale and reliability. Arch Gen Psychiatry 1978; 35: 773- 82
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (4th edn) (DSM-IV). APA, 1994.
30. Endicott J, Spitzer RL. A diagnostic interview: The schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978; 35: 837-44.
31. Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
32. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-35.
33. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
34. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-5.
35. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): The CGI-BP. Psychiatr Res 1997; 73: 159-71.
36. Coppen A, Montgomery SA, Gupta RK, Bailey JE. A double-blind comparison of lithium carbonate and maprotiline in the prophylaxis of the affective disorders. Br J Psychiatry 1976; 128: 79-85.
37. Delis D, Kramer J, Kaplan E, Ober BA. The California Verbal Learning Test. Psychological Corporation, 1987.
38. Jacoby LL. Invariance in automatic influences of memory: Toward a user's guide for the process-dissociation procedure. J Exp Psychol Learn Mem Cogn 1998; 24: 3-26.
39. van Gorp WG, Altshuler L, Theberge DC, Mintz J. Declarative and procedural memory in bipolar disorder. Biol Psychiatry 1999; 46: 525-31.
40. Martinez-Aran A, Vieta E, Colom F, Reinares M, Benabarre A, Torrent C, et al. Neuropsychological performance in depressed and euthymic bipolar patients. Neuropsychobiology 2002; 46 (suppl 1): 16-21.
41. MacQueen GM, Galway TM, Hay J, Young LT, Joffe RT. Recollection memory deficits in patients with major depressive disorder predicted by past depressions but not current mood state or treatment status. Psychol Med 2002; 32: 251-8.
42. Reitan R. The relation of the trail making test to organic brain damage. J Consult Psychol 1955; 19: 393-4.
43. Tipper SP. The negative priming effect: Inhibitory priming by ignored objects. Q J Exp Psychol A 1985; 37: 571-90.
44. Posner MI, Cohen Y. Components of visual orienting. In Attention and Performance X: Control of Language Processes (eds H Bouma, D Bouwhuis): 531-56. Erlbaum, 1984.
45. MacQueen GM, Grof P, Alda M, Marriott M, Young LT, Duffy A. A pilot study of visual backward masking performance among affected versus unaffected offspring of parents with bipolar disorder. Bipolar Disord 2004; 6: 374-8.
46. Gillman PK. CNS toxicity involving methylene blue: The exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. J Psychopharmacol 2011; 25: 429-36.
47. US Food and Drug Administration. FDA Drug Safety Communication: Serious CNS Reactions Possible when Methylene Blue is Given to Patients Taking Certain Psychiatric Medications. FDA, 2011 (http://www.fda.gov/Drugs/ DrugSafety/ucm263190.htm).
48. US Food and Drug Administration. FDA Drug Safety Communication: Updated Information about the Drug Interaction Between Methylene Blue (Methylthioninium Chloride) and Serotonergic Psychiatric Medications. FDA, 2011 (http://www.fda.gov/Drugs/DrugSafety/ucm276119.htm).